Arrowhead Pharmaceuticals, Inc.
ARWR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000879407
In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.73B in total; no superinvestor holds it.
Holders of 5% or more of ARWR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Arrowhead Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 10.10%14.2M shares | −2.10 ppfrom 12.20% | Apr 23, 20254 filings | Jul 27, 2026 | SEC |
| Avoro Capital Advisors LLC | 13G/A | 9.64%13.8M shares | +1.34 ppfrom 8.30% | Feb 14, 20253 filings | Aug 14, 2026 | SEC |
| FMR LLC | 13G | 5.20%7.35M shares | New | May 6, 20261 filing | May 6, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.05%7.08M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
19 Schedule 13D and 13G filings on Arrowhead Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20269:00 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 9.64%13.8M shares | +1.34 ppfrom 8.30% | Jun 30, 2026 | SEC |
| Jul 31, 202611:20 AM ET | Vanguard Portfolio Management LLC | 13G/A | 4.53%6.38M shares | −0.66 ppfrom 5.19%Below 5% | Jun 30, 2026 | SEC |
| Jul 27, 20264:25 PM ET | BlackRock, Inc. | 13G/A | 10.10%14.2M shares | −2.10 ppfrom 12.20% | Jun 30, 2026 | SEC |
| May 6, 202611:00 AM ET | FMR LLCand 1 other | 13G | 5.20%7.35M shares | New | Mar 31, 2026 | SEC |
| Apr 29, 20264:44 PM ET | Vanguard Capital Management LLC | 13G | 5.05%7.08M shares | New | Mar 31, 2026 | SEC |
| Apr 28, 20264:05 PM ET | Vanguard Portfolio Management LLC | 13G | 5.19%7.27M shares | New | Mar 31, 2026 | SEC |
| Apr 24, 20264:11 PM ET | BlackRock, Inc. | 13G/A | 12.20%17.1M shares | −2.80 ppfrom 15.00% | Mar 31, 2026 | SEC |
| Mar 26, 20263:43 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −11.24 ppfrom 11.24%Below 5% | Mar 13, 2026 | SEC |
| Jan 21, 202612:30 PM ET | BlackRock, Inc. | 13G/A | 15.00%20.3M shares | +1.20 ppfrom 13.80% | Dec 31, 2025 | SEC |
| Aug 15, 20255:28 PM ET | Sarepta Therapeutics, Inc.and 1 other | 13D/A | 0.00%0 shares | −9.50 ppfrom 9.50%Below 5% | Aug 13, 2025 | SEC |
| Aug 14, 20257:07 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 8.30%11.5M shares | −1.30 ppfrom 9.60% | Jun 30, 2025 | SEC |
| Aug 11, 20257:01 AM ET | State Street Corp | 13G | 4.60%6.37M shares | −0.50 ppfrom 5.10%Below 5% | Jun 30, 2025 | SEC |
| Jul 29, 202511:20 AM ET | Vanguard Group Inc | 13G/A | 11.24%15.5M shares | – | Jun 30, 2025 | SEC |
| May 13, 202510:26 AM ET | State Street Corp | 13G | 5.10%7.00M shares | +0.30 ppfrom 4.80% | Mar 31, 2025 | SEC |
| Apr 23, 20258:14 PM ET | BlackRock, Inc. | 13G/A | 13.80%19.0M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20255:23 PM ET | Sarepta Therapeutics, Inc.and 1 other | 13D | 9.50%11.9M shares | New | Feb 7, 2025 | SEC |
| Feb 14, 20259:31 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 9.60%12.0M shares | – | Dec 31, 2024 | SEC |
| Feb 5, 20256:41 AM ET | State Street Corp | 13G | 4.80%6.02M shares | NewBelow 5% | Dec 31, 2024 | SEC |
| Feb 10, 2021 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Arrowhead Pharmaceuticals, Inc. shares.
No Form 144 notices for Arrowhead Pharmaceuticals, Inc. are on file.